Abdel-Qader, A., Hassan, F., Mohammad, M. (2018). Low-Molecular–Weight Heparin versus Unfractionated Heparin in Pregnant Women with Recurrent Abortion associated with Antiphospholipid Syndrome. test, 73(5), 6616-6620. doi: 10.21608/ejhm.2018.15592
Abdel–Qader Farag Abdel-Qader; Farid Ibrahim Hassan; Mofeed Fawzy Mohammad. "Low-Molecular–Weight Heparin versus Unfractionated Heparin in Pregnant Women with Recurrent Abortion associated with Antiphospholipid Syndrome". test, 73, 5, 2018, 6616-6620. doi: 10.21608/ejhm.2018.15592
Abdel-Qader, A., Hassan, F., Mohammad, M. (2018). 'Low-Molecular–Weight Heparin versus Unfractionated Heparin in Pregnant Women with Recurrent Abortion associated with Antiphospholipid Syndrome', test, 73(5), pp. 6616-6620. doi: 10.21608/ejhm.2018.15592
Abdel-Qader, A., Hassan, F., Mohammad, M. Low-Molecular–Weight Heparin versus Unfractionated Heparin in Pregnant Women with Recurrent Abortion associated with Antiphospholipid Syndrome. test, 2018; 73(5): 6616-6620. doi: 10.21608/ejhm.2018.15592

Low-Molecular–Weight Heparin versus Unfractionated Heparin in Pregnant Women with Recurrent Abortion associated with Antiphospholipid Syndrome

The Egyptian Journal of Hospital Medicine
Article 4, Volume 73, Issue 5, October 2018, Pages 6616-6620    PDF (493.57 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2018.15592
Authors
Abdel–Qader Farag Abdel-Qader* ; Farid Ibrahim Hassan; Mofeed Fawzy Mohammad
Department of Obstetrics and Gynaecology, Faculty of Medicine, Alazhar University, Cairo, Egypt
Abstract
Objectives: to compare the efficacy and safety of the combination of unfractionated heparin  )UFH(  and Low Dose Aspirin (LDA)  with  that  of  low-molecular-weight heparin )LMWH(  and  LDA in  the  management  of  pregnant women with recurrent pregnancy loss secondary to antiphospholipid syndrome (APS). Methods : In a randomized prospective study, 60 women with a history of 3 or more consecutive spontaneous abortions and positive antiphospholipid antibodies were assigned in equal numbers to receive either UFH (5000 units, twice daily) plus LDA, or LMWH (enoxaparin 40 mg, once daily) plus LDA as soon as pregnancy was diagnosed. Results:  Twenty-four women in the LMWH group (80%) compared to 20 women in the UFH group (66.67%) delivered a viable infant (p >0.05). There was no significant difference in pregnancy complications or neonatal morbidity between the 2 groups. There were no incidences of excessive bleeding, thrombocytopenia, or osteoporotic fractures of excessive bleeding, thrombocytopenia, or osteoporotic fractures in either group. Conclusion: In this study, the use of LDA in combination with LMWH during pregnancy for the prevention of recurrent pregnancy loss in women with antiphospholipid syndrome seems to be as safe as UFH plus LDA. Large randomized trials will be required to determine differences in outcome with LMWH and LDA compared with treatment with UFH combined with LDA in this group of patients.
Keywords
recurrent pregnant loss; Antiphospholipid antibodies; low molecular weight heparin; unfractionated heparin
Statistics
Article View: 393
PDF Download: 924